WIN Consortium collaborates with DECISION & STRATEGIE SANTE in media partnership

Posted: Thursday, May 17, 2018


The Worldwide Innovative Network (WIN) Consortium is proud to announce a media partnership with DECISION & STRATEGIE SANTE. They have come together to collaborate in the mutual promotion of their annual conferences.

The WIN Consortium will celebrate its 10th year Anniversary edition of the WIN Symposia at the WIN Symposium 2018 in Paris, France on 25-26 June 2018. “Global Implementation of Precision Oncology: WINning the War against Cancer” is this year’s theme for this celebratory event.

DECISION & STRATEGIE SANTE organizes meetings for the attention of health professionals on topical topics. Their annual congress entitled "The Encounters of Cancer Cancer" (RCFr 2018) is intended to present the main scientific, medical, technological and present and expected organizational structures in the many fields of modern cancerology. Their forthcoming conference will take place on 27-28 November 2018 at Chateauform 'Georges V – Paris, France.

About:
The Worldwide Innovative Network (WIN) is a nonprofit organization dedicated to cancer research that organizes innovative clinical trials and organizes an annual symposium on advances in personalized medicine.

DECISION & STRATEGIE SANTE is a health communication company, leader in hospital and institutional markets. It brings together all the training, communication, publishing and event management specialized in health.

WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, health plans, and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.

WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.

WIN now includes 43 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.

Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.

Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
Our members include 30 leading academic centers representing 18 countries and four continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.

WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.
WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually in Paris, brings together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.